High cost, highly specialised therapies
Date published: 30 July 2025
IHACPA does not have a role in the decision-making processes that inform the inclusion of a highly specialised therapy in NHRA funding arrangements.
In line with provisions under the Addendum to the National Health Reform Agreement 2020–26, IHACPA’s remit is to establish eligibility, scope and reporting criteria for in-scope high cost, highly specialised therapies for Commonwealth funding.
For information on our role in the assessment of new health technologies, please view New Health Technologies